Enclomiphene vs Pancragen
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EnclomipheneAnti-Aging & Longevity
Pancragen- Summary
- Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that stimulates endogenous testosterone production by blocking estrogen negative feedback on the hypothalamus and pituitary. Unlike TRT, it restores testosterone while preserving or increasing sperm production and testicular volume.
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Half-Life
- 5-7 days (long half-life; accumulates)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 12.5-25 mg per day
- 10 mg per day
- Frequency
- Once daily or every other day
- Daily for 10–30 days
- Key Benefits
- Restores testosterone to normal range without exogenous androgen administration
- Preserves or increases sperm production and fertility
- Maintains testicular volume (unlike TRT which causes testicular atrophy)
- LH and FSH levels rise, indicating intact HPG axis function
- Option for hypogonadal men desiring fertility
- Oral administration (no injection required)
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Side Effects
- Visual disturbances (rare but class-related SERM effect)
- Mood changes or irritability
- Hot flashes
- Elevated estradiol in some users
- +2 more
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Stacks With
- —
- —